NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner

Rhea-AI Summary

NeuroMetrix (NASDAQ: NURO) has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. C2SHIP, a National Science Foundation-funded consortium, aims to develop technologies for personalized at-home healthcare. NeuroMetrix will apply its Quell® wearable neuromodulation technology and the Quell Health Cloud chronic pain database for novel therapeutic applications. This partnership seeks to enhance chronic pain management and improve patient outcomes through advanced data science and collaboration with leading academic institutions.

Positive

• Partnership with C2SHIP to enhance technology for personalized at-home healthcare.
• Focus on Quell® technology to innovate chronic pain management solutions.
• Collaboration with prestigious academic institutions to leverage data science.

Negative

• None.

WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.

C2SHIP is a U.S. National Science Foundation (NSF) funded consortium of leading academic centers and industry partners with a mission to develop technologies and approaches for high-quality personalized healthcare that is delivered at-home. The initial four participating academic centers are the University of Arizona, Baylor College of Medicine, University of Southern California and the California Institute of Technology.

In this collaboration, NeuroMetrix will focus on novel therapeutic applications of its Quell^® wearable neuromodulation technology and leveraging the information in the Quell Health Cloud chronic pain database using data science expertise at the participating academic centers.

“One of the key goals of C2SHIP is accelerating translation of cutting-edge technologies to patients’ care in-place, while training students and fellows in remote patient care," said Bijan Najafi, Ph.D., Professor of Surgery, Director of Clinical Research at the Division of Vascular Surgery and Director of C2SHIP at the Baylor College of Medicine. "We are pleased to welcome NeuroMetrix to C2SHIP as one of our industrial members. NeuroMetrix’s innovative product called Quell is well suited to the mission of C2SHIP. We are hoping with the support of C2SHIP that we will accelerate its integration for the in-place management of chronic pain, remote monitoring of pain and its impact on mobility, and to empower patients to select personalized pain management regimes to better move through the world."

"We are honored to join C2SHIP and look forward to a productive partnership with the participating academic centers, which are among the top biomedical research institutions in the country. Through these collaborations we hope to advance Quell technology to further benefit patients,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix."

About C2SHIP

The mission of the Center to Stream Healthcare In Place (C2SHIP) is to engage academic and industrial partners in joint efforts that develop healthcare technologies for in-place care and accelerate innovation through multi-specialty collaborations. The Center's strategy is to emphasize fundamental investigations that provide an in-depth understanding of the core disciplines needed for personalized technology that promotes in-place care, to establish effective interactions with Center members to promote innovation capacity and accelerate technology transfer, and to promote collaborations with other existing centers to create multi-center innovative technology for the involved core disciplines. C2SHIP is part of the U.S. National Science Foundation (NSF) Industry/University Cooperative Research Centers (I/UCRC) program. For more information visit C2SHIP.org.

About NeuroMetrix

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck^® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE^® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell^® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit NeuroMetrix.com.

Source: NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com

FAQ

What is the significance of NeuroMetrix joining C2SHIP?

NeuroMetrix's partnership with C2SHIP aims to advance its Quell® technology for personalized chronic pain management, enhancing patient care through innovative healthcare solutions.

How will NeuroMetrix and C2SHIP collaborate?

NeuroMetrix will utilize its Quell® wearable neuromodulation technology and the Quell Health Cloud to collaborate with academic centers on chronic pain management.

What is the goal of the Center to Stream Healthcare In Place (C2SHIP)?

C2SHIP's goal is to develop healthcare technologies for in-home care and accelerate innovation through collaboration among academic and industry partners.

What technology does NeuroMetrix market?

NeuroMetrix markets the Quell® wearable neuromodulation device for chronic pain treatment, along with other diagnostic devices for neurological disorders.

When did NeuroMetrix announce its partnership with C2SHIP?

NeuroMetrix announced its partnership with C2SHIP on October 5, 2021.